Cancer BiologybioRxiv
A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia
A. L. Smith, A. P. Eiken, D. Y. Moore…·D. El-Gamal
This study shows that SRX3305, a triple-action inhibitor targeting BTK, PI3K, and BRD4, reduces CLL cell proliferation, promotes apoptosis, and blocks migration in preclinical models.
DOI 10.3390/ijms23126712